Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Selenoprotein O (SELENOO) is the largest mammalian selenoprotein, localized to mitochondria, and contains selenocysteine (Sec), a rare amino acid encoded by a UGA stop codon using a specialized RNA structure (SECIS element)[3][4][5]. SELENOO catalyzes the covalent transfer of adenosine monophosphate (AMP) onto serine, threonine, or tyrosine residues of target proteins, a modification known as AMPylation, particularly on proteins involved in redox homeostasis[2][4]. This activity suggests SELENOO helps regulate mitochondrial redox function and the cellular response to oxidative stress, but its full physiological roles remain incompletely defined[1][2][3][4]. SELENOO is evolutionarily conserved from bacteria to humans and is grouped among the lesser-known “alphabet selenoproteins” implicated broadly in antioxidant and redox-related processes[1]. There is currently no clinical use for SELENOO as a biomarker or therapeutic target, and no drugs are known to directly interact with it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Selenoprotein O (SELENOO).